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Our understanding of microbial pathogenesis is founded largely on the assumption that the
microbe responsible for causing a disease is the one that is abundantly present at the time and site
of disease symptoms. This situation can be compared to the scenario in which a criminal is caught
red-handed at the scene of the crime. In this article, we discuss an alternative scenario—“covert
pathogenesis”—in which a microbe acts more like a covert operative, sneaking in undetected or
unrecognized to trigger disease onset, escaping before the damage is noticed. Here, we will further
define “covert pathogenesis,” describe an example of this phenomenon discovered in the urinary
tract, highlight other scenarios or diseases that could be impacted by this paradigm, and discuss
implications for diagnosis and treatment.

What is “covert pathogenesis”?
Perhaps the easiest way to define “covert pathogenesis” is to first clarify what it is not. Although
covert pathogenesis could involve more than one bacterial species (as in the examples described
below), it is different from a polymicrobial infection, in which multiple organisms are present at
the same time and in the same location, working in synergy to cause disease. Covert pathogenesis is not simply an alternative term for quiescent latent infection by a recognized primary pathogen and is not to be confused with what is referred to as “covert infection” in the viral field,
which encompasses nonproductive latency or persistent low level nonlethal infection [1].
Rather, covert pathogenesis, here, refers to a situation whereby a microbe contributes to disease
onset, progression, or severity even though it is not present at the time and place of disease itself.
The key feature of covert pathogenesis that distinguishes it from other recognized disease mechanisms is the absence of the covert pathogen at the time and site of disease presentation. In
other words, a covert pathogen could never be “caught red-handed” at the scene of the crime.

Are there known examples of covert pathogens?
The urinary tract is one of the most common sites of infection in humans [2]. Escherichia coli
is often “caught red-handed” in urine collected at the time patients are experiencing symptoms
(increased urination frequency and urgency that is often painful). It is believed that E. coli
gains access to the urinary tract by mechanical transfer from nearby microbial niches. Sexual
activity is a leading risk factor for urinary tract infection (UTI), presumably because it aids
in the transfer of E. coli from these nearby niches to the urinary tract [2]. Both the vagina and
gastrointestinal tract contain a wealth and diversity of bacterial species. Therefore, when
mechanical transfer of bacteria from these niches does occur, the exposure is most certainly
polymicrobial in nature. Here, we will discuss our new model that examined the impact of
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urinary tract exposures to the vaginal bacterium Gardnerella vaginalis, which exemplifies the
covert pathogenesis paradigm.
G. vaginalis is most widely known as a frequent member of the vaginal microbiome, particularly in the context of the dysbiosis known as bacterial vaginosis (BV) [3–6]. G. vaginalis is a
rare cause of symptomatic UTI, but multiple studies have detected (either by culturing or
sequencing) Gardnerella in urine samples from women [7–10]. Also of note, women with BV
have higher rates of UTI than those with a “healthy” lactobacillus-dominated vaginal microbiota
[11–14]. Our recent study in mice showed inoculation of the bladder with G. vaginalis triggered
the cells lining the bladder surface to undergo noninflammatory cell death accompanied by
exfoliation [15]. Previous studies have shown that, in mice, E. coli can establish latent infection
in intracellular tissue reservoirs in the bladder that can persist for long periods [16–18] (Fig 1,
left panel). In humans, sequential UTI episodes are often (up to two-thirds of cases) caused by
the same strain of E. coli, supporting the concept of emergence from a bladder reservoir [19].
Other studies in mice have demonstrated that treatment of the bladder with agents that induce
exfoliation of the epithelium can trigger egress of E. coli to cause recurrent UTI (rUTI) [20–22].
Consistent with these previous studies, our model of bladder exposure to G. vaginalis in mice
harboring E. coli reservoirs resulted in exfoliation (Fig 1, center panel) and also triggered rUTI
marked by E. coli and neutrophils in urine [15] (Fig 1, right panel). In contrast, bladder exposure to Lactobacillus crispatus (widely regarded as a “healthy” vaginal bacterium) caused neither
exfoliation nor rUTI. In this mouse model, G. vaginalis was rapidly cleared (by 12 hours after
inoculation) and was no longer present in urine at the time point of E. coli emergence. Therefore, G. vaginalis appears to act as a covert pathogen to promote E. coli rUTI [15].

Are there other diseases in which covert pathogenesis could be
important?
The example of G. vaginalis reawakening latent E. coli infection highlights the possibility that
other members of the urogenital microbiome could also act as covert pathogens capable of

Fig 1. Gardnerella vaginalis is a covert pathogen in the bladder. (Left panel) A schematic representation of Escherichia coli reservoirs,
which become established within bladder epithelial cells during infection in mice. (Right panel) Schematic illustration of what happens
when the bladder tissue is exposed to Gardnerella vaginalis, namely, that epithelial cells are exfoliated and E. coli emerges from the
epithelium to cause another UTI. Host neutrophils enter the tissue only upon E. coli emergence, illustrating the concept that E. coli is
“caught red-handed” whereas G. vaginalis is no longer detectable at the time of a recurrent UTI. UTI, urinary tract infection.
https://doi.org/10.1371/journal.ppat.1007586.g001
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triggering rUTI. Furthermore, the covert pathogenesis paradigm may be involved in reactivation of other latent infections outside of the urinary tract. Current estimates are that nearly
one quarter of the world’s population (approximately 1.7 billion people) have latent tuberculosis (TB) infection in their lungs. Although reactivation of TB is more common in people with
compromised immunity (HIV+, transplant patients, or those with autoimmune disorders on
immunosuppressive drugs) [23], the causes of TB reactivation in otherwise healthy individuals
are unclear. We postulate that the covert pathogenesis mechanism could play a role in these
cases. The airway is an open system, exposed to a variety of microbes with each breath.
Although still somewhat controversial, studies suggest the existence of an airway and/or lung
microbiota, which may play roles in immune fitness and various inflammatory and infectious
diseases. A few studies have examined the microbiota of sputum comparing patients with
active TB to healthy controls [24–27]. Future studies in mouse models could investigate
whether covert pathogenesis plays a role in TB reactivation by exposing mice with latent TB to
bacteria found in the “airway microbiome,” then monitoring for reactivation of TB infection.
Likewise, longitudinal studies in humans could examine whether the presence of certain
organisms in sputum precedes the development of active TB.
Covert pathogenesis may represent an emerging paradigm relevant in situations in which
the natural triggers of disease have remained obscure, including those that have a long history
of being deemed noninfectious because standard culture techniques have failed to consistently
find high levels of a single organism. The etiologies of several conditions associated with lower
urinary symptoms (bladder pain syndrome, interstitial cystitis, urgency incontinence) fit into
this category. The existence of a “urinary microbiome” is becoming more established in the literature, with several studies finding differences in bacterial populations in urine in the context
of health versus disease. For example, a recent study detected G. vaginalis and a handful of
other bacterial species more frequently in women with urgency urinary incontinence [9,10].
Even though longitudinal studies have yet to establish whether or not the urinary microbiome
represents an established community or reflects the existence of routine transient exposures,
the covert pathogenesis model shows that long-standing colonization of the bladder need not
be required in order for bacteria to affect disease outcomes.
One can also imagine numerous other situations in which mucosal surfaces (e.g., mouth,
throat, gut, vagina) are transiently exposed to microbes found in food, genital secretions, or
inhaled particulates, leading to fundamental changes in the body’s interaction with existing
microbes or latent pathogens. Furthermore, soluble toxins produced by a microbe at a distant
site could also fall under the covert pathogenesis paradigm if the toxin is undetectable at the
time and body site of disease presentation. Covert pathogen interactions could also lead to
imbalances in the immune response or tissue homeostasis, resulting in inappropriate allergic,
inflammatory, autoimmune diseases, or even cancer, even though the inciting microbial exposure is no longer present at the time the disease manifests.

What are the implications and challenges of covert pathogenesis
for diagnosis and/or treatment?
Identification of “covert pathogens” in the context of diseases in humans is challenging
because the culprits are absent at the time and site of disease presentation. Therefore, in many
instances, a longitudinal study design will be necessary to capture these situations. However,
in some cases, a covert pathogen may reside in another bodily reservoir, offering alternative
opportunities for diagnosis and intervention. For example, the finding that G. vaginalis may be
a trigger of E. coli emergence from bladder reservoirs suggests that therapies aimed at reducing
G. vaginalis vaginal colonization may help protect against E. coli rUTI. An estimated 1% (70
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million worldwide) of women suffer more than six rUTIs each year [2]. Preventing rUTI and
subsequent pyelonephritis and systemic infection by targeting G. vaginalis is an exciting concept given the alarming global rise in multidrug resistant E. coli [28–30]. Such approaches
should be feasible because G. vaginalis is typically sensitive to clindamycin and metronidazole,
two drugs that are often used successfully to treat women with BV.

Conclusions
The human body is constantly being exposed to microbes. Current paradigms in infectious
disease pathogenesis typically assume that these exposures are benign unless the microbe takes
up residence, multiplies to high levels, and is detectable at the time and in the tissue where
symptoms occur. Moving forward, we ought to be vigilant to the possibility that, in some
cases, even transient microbial exposures may result in tissue damage or host responses that
could result in disease long after a microbe has been cleared.
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